Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN)
- PMID: 25964057
- PMCID: PMC4521391
- DOI: 10.1111/neup.12205
Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN)
Abstract
It has been hypothesized that the relatively rare autosomal dominant Alzheimer disease (ADAD) may be a useful model of the more frequent, sporadic, late-onset AD (LOAD). Individuals with ADAD have a predictable age at onset and the biomarker profile of ADAD participants in the preclinical stage may be used to predict disease progression and clinical onset. However, the extent to which the pathogenesis and neuropathology of ADAD overlaps with that of LOAD is equivocal. To address this uncertainty, two multicenter longitudinal observational studies, the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN), leveraged the expertise and resources of the existing Knight Alzheimer Disease Research Center (ADRC) at Washington University School of Medicine, St. Louis, Missouri, USA, to establish a Neuropathology Core (NPC). The ADNI/DIAN-NPC is systematically examining the brains of all participants who come to autopsy at the 59 ADNI sites in the USA and Canada and the 14 DIAN sites in the USA (eight), Australia (three), UK (one) and Germany (two). By 2014, 41 ADNI and 24 DIAN autopsies (involving nine participants and 15 family members) had been performed. The autopsy rate in the ADNI cohort in the most recent year was 93% (total since NPC inception: 70%). In summary, the ADNI/DIAN NPC has implemented a standard protocol for all sites to solicit permission for brain autopsy and to send brain tissue to the NPC for a standardized, uniform and state-of-the-art neuropathologic assessment. The benefit to ADNI and DIAN of the implementation of the NPC is very clear. The NPC provides final "gold standard" neuropathological diagnoses and data against which the antecedent observations and measurements of ADNI and DIAN can be compared.
Keywords: PET-PiB amyloid imaging; autosomal dominant Alzheimer disease; late-onset Alzheimer disease; neuropathologic diagnostic criteria; neuropathologic heat map.
© 2015 Japanese Society of Neuropathology.
Figures



Similar articles
-
Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core.Alzheimers Dement. 2010 May;6(3):274-9. doi: 10.1016/j.jalz.2010.03.012. Alzheimers Dement. 2010. PMID: 20451876 Free PMC article.
-
The role of the Alzheimer's Disease Neuroimaging Initiative in establishing the Dominantly Inherited Alzheimer Network.Alzheimers Dement. 2024 Aug;20(8):5789-5791. doi: 10.1002/alz.14106. Epub 2024 Jul 3. Alzheimers Dement. 2024. PMID: 38958563 Free PMC article.
-
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.JAMA Neurol. 2023 Dec 1;80(12):1353-1363. doi: 10.1001/jamaneurol.2023.3618. JAMA Neurol. 2023. PMID: 37843849 Free PMC article.
-
Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants.Alzheimers Dement. 2015 Jul;11(7):815-22. doi: 10.1016/j.jalz.2015.05.010. Alzheimers Dement. 2015. PMID: 26194314 Free PMC article. Review.
-
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.Rev Neurol (Paris). 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6. Rev Neurol (Paris). 2013. PMID: 24016464 Free PMC article. Review.
Cited by
-
Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics.J Biol Chem. 2019 Jan 18;294(3):1045-1058. doi: 10.1074/jbc.RA118.004471. Epub 2018 Nov 26. J Biol Chem. 2019. PMID: 30478174 Free PMC article.
-
Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease.Ann Neurol. 2018 Nov;84(5):741-753. doi: 10.1002/ana.25344. Epub 2018 Oct 25. Ann Neurol. 2018. PMID: 30246887 Free PMC article.
-
Genetic Phenotypes of Alzheimer's Disease: Mechanisms and Potential Therapy.Phenomics. 2023 Apr 3;3(4):333-349. doi: 10.1007/s43657-023-00098-x. eCollection 2023 Aug. Phenomics. 2023. PMID: 37589021 Free PMC article. Review.
-
Gut Microbiome-Modified Polyphenolic Compounds Inhibit α-Synuclein Seeding and Spreading in α-Synucleinopathies.Front Neurosci. 2020 May 4;14:398. doi: 10.3389/fnins.2020.00398. eCollection 2020. Front Neurosci. 2020. PMID: 32431588 Free PMC article.
-
Clinically early-stage CSPα mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss.Acta Neuropathol Commun. 2015 Nov 26;3:73. doi: 10.1186/s40478-015-0256-5. Acta Neuropathol Commun. 2015. PMID: 26610600 Free PMC article.
References
-
- Alafuzoff I, Pikkarainen M, Arzberger T, Thal DR, Al-Sarraj S, Bell J, Bodi I, Budka H, Capetillo-Zarate E, Ferrer I, et al. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol. 2008;115:533–546. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical